• Behnood Bikdeli, Mahesh V Madhavan, David Jimenez, Taylor Chuich, Isaac Dreyfus, Elissa Driggin, Nigoghossian Caroline Der C NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York., Walter Ageno, Mohammad Madjid, Yutao Guo, Liang V Tang, Yu Hu, Jay Giri, Mary Cushman, Isabelle Quéré, Evangelos P Dimakakos, C Michael Gibson, Giuseppe Lippi, Emmanuel J Favaloro, Jawed Fareed, Joseph A Caprini, Alfonso J Tafur, John R Burton, Dominic P Francese, Elizabeth Y Wang, Anna Falanga, Claire McLintock, Beverley J Hunt, Alex C Spyropoulos, Geoffrey D Barnes, John W Eikelboom, Ido Weinberg, Sam Schulman, Marc Carrier, Gregory Piazza, Joshua A Beckman, P Gabriel Steg, Gregg W Stone, Stephan Rosenkranz, Samuel Z Goldhaber, Sahil A Parikh, Manuel Monreal, Harlan M Krumholz, Stavros V Konstantinides, Jeffrey I Weitz, Lip Gregory Y H GYH Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom; Aalborg Universit, and Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function.
• NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York; Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York. Electronic address: bb2813@cumc.columbia.edu.
• J. Am. Coll. Cardiol. 2020 Jun 16; 75 (23): 2950-2973.

AbstractCoronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

32 keywords...

hide…